118
Participants
Start Date
January 10, 2007
Primary Completion Date
September 17, 2009
Study Completion Date
September 17, 2009
Motavizumab
A single IV dose of motavizumab 30 mg/kg or 100 mg/kg will be administered on Day 0 of the study.
Placebo
A single IV dose of placebo matched to motavizumab will be administered on Day 0 of the study.
Research Site, Auckland
Research Site, Herston
Research Site, Palmerston North
Research Site, New Hyde Park
Research Site, Brooklyn
Research Site, Mineola
Research Site, Syracuse
Research Site, Buffalo
Research Site, Rochester
Research Site, Morgantown
Research Site, Columbus
Research Site, Milwaukee
Research Site, Oak Lawn
Research Site, Chicago
Research Site, Omaha
Research Site, Dallas
Research Site, Houston
Research Site, Salt Lake City
Research Site, Tucson
Research Site, Long Beach
Research Site, San Diego
Research Site, Orange
Research Site, Honolulu
Research Site, Portland
Research Site, Seattle
Research Site, Santiago
Research Site, Santiago
Research Site, Jacksonville
Research Site, Independencia
Research Site, Santiago
Research Site, Hamilton
Research Site, Panama City
Research Site, Boston
Research Site, Jackson
Research Site, Oklahoma City
Lead Sponsor
MedImmune LLC
INDUSTRY